{"success":true,"data":{"pressRelease":{"id":"167322","rtpr_id":"nPNA1JCLNa-20261013","ticker":"6990","exchange":"HKEX","all_tickers":["6990"],"title":"Kelun-Biotech to Present Multiple Study Results at ESMO 2026","author":"PR Newswire","published_at":"2026-10-13T11:23:44.750Z","article_body":"Kelun-Biotech to Present Multiple Study Results at ESMO 2026\nPR Newswire\n\nCHENGDU, China, Oct. 13, 2026\n\nCHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for\nMedical Oncology (ESMO) Congress will be held in Madrid, Spain, from October\n23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\"\nor the \"Company\", 6990.HK) will present results from multiple clinical studies\nat the congress, including data from its trophoblast cell-surface antigen 2\n(TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan\n(sac-TMT, also known as SKB264/MK-2870)(佳泰莱(®)) and another ADC.\n\n\nAmong them, multiple research findings for sac-TMT have been selected for oral\npresentations, including the Phase III OptiTROP-Lung04 and OptiTROP-Lung06\nstudies, which have both been selected for the \"Non-Small Cell Lung Cancer\n(NSCLC), Metastatic\" session and will be presented in the same time slot as\nproffered paper reports. In addition, data from the global pivotal Phase III\nTroFuse-005 trial led by MSD([1]) will be presented for the first time in the\nESMO Presidential Symposium.\n\nThe abstract titles of the above studies as well as other studies from\nKelun-Biotech have been published on the official ESMO website. Details are as\nfollows:\n\n Lung cancer                                                                                                                                                                                                                                                                                                                                               \n Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study  LBA66, Proffered paper | NSCLC, metastatic October 25, 10:15 to 11:45 local time                                 \n Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study                              LBA67, Proffered paper | NSCLC, metastatic October 25, 10:15 to 11:45 local time                                 \n SKB500 (a novel B7-H3–targeted antibody-drug conjugate) in patients with extensive-stage small cell lung cancer (ES-SCLC): Results from a Phase I study                                                                                  3816RO, Rapid oral | Non-metastatic NSCLC and other thoracic malignancies October 26, 10:15 to 11:45 local time  \n\n \n\n Breast cancer                                                                                                                                                                                                                                                                \n Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01  4639RO, Rapid oral | Breast cancer, advanced stage October 26, 10:15 to 11:45 local time  \n\n \n\n Gynecologic cancers                                                                                                                                                                                                                                                                          \n Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study                                                LBA11, Proffered Paper | Presidential Symposium October 26, 16:30 to 18:15 local time  \n Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC): Results from a Phase 2 study (2870-002/SKB264-II-06)  1259P, Poster | Gynaecological cancers October 26, 12:00 to 12:45 local time           \n\n \n\n Genitourinary cancers                                                                                                                                                                                                                                                                      \n Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a Phase 2 Study (2870-002/SKB264-II-06)  4739RO, Rapid oral | Genitourinary tumours, renal and urothelial October 24, 10:15 to 11:45 local time  \n\n \n\nAbout sac-TMT(佳泰莱(®))\n\nSac-TMT, a core product of the Company, is a novel TROP2 ADC in which the\nCompany has proprietary intellectual property rights, targeting advanced solid\ntumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological\ntumors and genitourinary tumors, among others. Sac-TMT is developed with a\nunique, bifunctional linker that maximizes payload delivery to tumor cells\nboth through its irreversible connection with the anti-TROP2 monoclonal\nantibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative\ntopoisomerase I inhibitor payload (KL610023) in the lysosome, with a\ndrug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on\nthe surface of tumor cells by recombinant anti-TROP2 humanized monoclonal\nantibodies, which is then endocytosed by tumor cells and releases the payload\nKL610023 intracellularly. KL610023 induces DNA damage to tumor cells, which in\nturn leads to cell-cycle arrest and apoptosis. In addition, it also releases\nKL610023 in the tumor microenvironment. Given that KL610023 is membrane\npermeable, it can enable a bystander effect, or in other words kill adjacent\ntumor cells.\n\nIn May 2022, the Company licensed the exclusive rights to MSD (the tradename\nof Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and\ncommercialize sac-TMT in all territories outside of Greater China (which\nincludes Mainland China, Hong Kong, Macao and Taiwan).\n\nTo date, four indications for sac-TMT have been approved and marketed in China\nfor: 1) unresectable locally advanced or metastatic triple-negative breast\ncancer (TNBC) who have received at least two prior systemic therapies (at\nleast one of them for advanced or metastatic setting); 2) epidermal growth\nfactor receptor (EGFR) mutant-positive locally advanced or metastatic\nnon-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor\n(TKI) therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally\nadvanced or metastatic non-squamous NSCLC who progressed after treatment with\nEGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive\n(HR+)/human epidermal growth factor receptor 2-negative (HER2-)\n(Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-)\nBC who have received prior endocrine therapy and at least one line of\nchemotherapy in advanced setting. The first two indications above have been\nincluded in China's National Reimbursement Drug List (NRDL). This inclusion is\nexpected to bring clinically meaningful benefits to a greater number of\npatients with BC and NSCLC. Additionally, sac-TMT has been granted six\nBreakthrough Therapy Designations by the NMPA.\n\nSac-TMT is the world's first TROP2 ADC drug approved for marketing in lung\ncancer. Two new indication applications have been accepted for review by the\nNMPA: 1) sac-TMT in combination with pembrolizumab as first‑line treatment\nfor locally advanced or metastatic NSCLC who have programmed cell death ligand\n1 (PD-L1) tumor proportion score (TPS) ≥1% and are EGFR-negative and\nALK-negative; 2) sac‑TMT as first‑line treatment for patients with\nrecurrent or metastatic TNBC who have a PD‑L1 combined positive score (CPS)\n<10 or have recurred after prior programmed cell death protein 1\n(PD-1)/PD‑L1 inhibitor therapy in the early stage, both of the above two\napplications have been included in the priority review and approval process.\nAs of today, the Company has initiated 9 registrational clinical studies in\nChina. MSD has initiated 18 ongoing global Phase III clinical studies of\nsac-TMT as a monotherapy or in combination with pembrolizumab or other\nanti-cancer agents for several types of cancer. These studies are sponsored\nand led by MSD.\n\nAbout SKB500\n\nSKB500 is a B7-H3-targeted ADC independently developed by the company using\nits OptiDC(TM) platform technology, featuring a site-specific cleavable linker\nand a potent topoisomerase I inhibitor. In the Phase I clinical study, SKB500\ndemonstrated robust efficacy and manageable safety profiles across multiple\nadvanced solid tumors. Currently, two Phase II studies of SKB500 in\nextensive-stage small cell lung cancer (ES-SCLC) and advanced esophageal\nsquamous cell carcinoma (ESCC),etc. are ongoing in China.\n\nAbout Kelun-Biotech\n\nKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which\nfocuses on the R&D, manufacturing, commercialization and global collaboration\nof innovative biological drugs and small molecule drugs. Kelun-Biotech focuses\non major disease areas such as solid tumors, autoimmune, and metabolic\ndiseases, and in establishing a globalized drug development and\nindustrialization platform to address the unmet medical needs in China and the\nrest of world. Kelun-Biotech is committed to becoming a leading global\nenterprise in the field of innovative drugs. At present, Kelun-Biotech has\nmore than 30 ongoing key innovative drug projects, of which 4 projects with 8\nindications have been approved for marketing, 2 projects with 3 indications\nare in the NDA stage and more than 10 projects are in the clinical stage.\nKelun-Biotech has established one of the world's leading proprietary ADC and\nnovel DC platforms, OptiDC(TM), and has 2 ADC projects with 5 indications\napproved for marketing, and multiple ADC and novel DC assets in clinical or\npreclinical research stage. For more information, please visit:\nhttps://en.kelun-biotech.com/.\n\n ([1])MSD is the tradename of Merck & Co., Inc, Rahway, NJ, USA.    \n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/kelun-biotech-to-present-multiple-study-results-at-esmo-2026-302906988.html\n\nSOURCE Kelun-Biotech\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1883382/20260715041831EDT_image_1.jpg?id=OA3015499\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNA1JCLNa-20261013","title":"Kelun-Biotech to Present Multiple Study Results at ESMO 2026","author":"PR Newswire","ticker":"6990","created":"2026-10-13T11:23:44.750Z","tickers":["6990"],"exchange":"HKEX","article_body":"Kelun-Biotech to Present Multiple Study Results at ESMO 2026\nPR Newswire\n\nCHENGDU, China, Oct. 13, 2026\n\nCHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for\nMedical Oncology (ESMO) Congress will be held in Madrid, Spain, from October\n23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (\"Kelun-Biotech\"\nor the \"Company\", 6990.HK) will present results from multiple clinical studies\nat the congress, including data from its trophoblast cell-surface antigen 2\n(TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan\n(sac-TMT, also known as SKB264/MK-2870)(佳泰莱(®)) and another ADC.\n\n\nAmong them, multiple research findings for sac-TMT have been selected for oral\npresentations, including the Phase III OptiTROP-Lung04 and OptiTROP-Lung06\nstudies, which have both been selected for the \"Non-Small Cell Lung Cancer\n(NSCLC), Metastatic\" session and will be presented in the same time slot as\nproffered paper reports. In addition, data from the global pivotal Phase III\nTroFuse-005 trial led by MSD([1]) will be presented for the first time in the\nESMO Presidential Symposium.\n\nThe abstract titles of the above studies as well as other studies from\nKelun-Biotech have been published on the official ESMO website. Details are as\nfollows:\n\n Lung cancer                                                                                                                                                                                                                                                                                                                                               \n Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study  LBA66, Proffered paper | NSCLC, metastatic October 25, 10:15 to 11:45 local time                                 \n Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study                              LBA67, Proffered paper | NSCLC, metastatic October 25, 10:15 to 11:45 local time                                 \n SKB500 (a novel B7-H3–targeted antibody-drug conjugate) in patients with extensive-stage small cell lung cancer (ES-SCLC): Results from a Phase I study                                                                                  3816RO, Rapid oral | Non-metastatic NSCLC and other thoracic malignancies October 26, 10:15 to 11:45 local time  \n\n \n\n Breast cancer                                                                                                                                                                                                                                                                \n Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01  4639RO, Rapid oral | Breast cancer, advanced stage October 26, 10:15 to 11:45 local time  \n\n \n\n Gynecologic cancers                                                                                                                                                                                                                                                                          \n Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study                                                LBA11, Proffered Paper | Presidential Symposium October 26, 16:30 to 18:15 local time  \n Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC): Results from a Phase 2 study (2870-002/SKB264-II-06)  1259P, Poster | Gynaecological cancers October 26, 12:00 to 12:45 local time           \n\n \n\n Genitourinary cancers                                                                                                                                                                                                                                                                      \n Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a Phase 2 Study (2870-002/SKB264-II-06)  4739RO, Rapid oral | Genitourinary tumours, renal and urothelial October 24, 10:15 to 11:45 local time  \n\n \n\nAbout sac-TMT(佳泰莱(®))\n\nSac-TMT, a core product of the Company, is a novel TROP2 ADC in which the\nCompany has proprietary intellectual property rights, targeting advanced solid\ntumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological\ntumors and genitourinary tumors, among others. Sac-TMT is developed with a\nunique, bifunctional linker that maximizes payload delivery to tumor cells\nboth through its irreversible connection with the anti-TROP2 monoclonal\nantibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative\ntopoisomerase I inhibitor payload (KL610023) in the lysosome, with a\ndrug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on\nthe surface of tumor cells by recombinant anti-TROP2 humanized monoclonal\nantibodies, which is then endocytosed by tumor cells and releases the payload\nKL610023 intracellularly. KL610023 induces DNA damage to tumor cells, which in\nturn leads to cell-cycle arrest and apoptosis. In addition, it also releases\nKL610023 in the tumor microenvironment. Given that KL610023 is membrane\npermeable, it can enable a bystander effect, or in other words kill adjacent\ntumor cells.\n\nIn May 2022, the Company licensed the exclusive rights to MSD (the tradename\nof Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and\ncommercialize sac-TMT in all territories outside of Greater China (which\nincludes Mainland China, Hong Kong, Macao and Taiwan).\n\nTo date, four indications for sac-TMT have been approved and marketed in China\nfor: 1) unresectable locally advanced or metastatic triple-negative breast\ncancer (TNBC) who have received at least two prior systemic therapies (at\nleast one of them for advanced or metastatic setting); 2) epidermal growth\nfactor receptor (EGFR) mutant-positive locally advanced or metastatic\nnon-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor\n(TKI) therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally\nadvanced or metastatic non-squamous NSCLC who progressed after treatment with\nEGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive\n(HR+)/human epidermal growth factor receptor 2-negative (HER2-)\n(Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-)\nBC who have received prior endocrine therapy and at least one line of\nchemotherapy in advanced setting. The first two indications above have been\nincluded in China's National Reimbursement Drug List (NRDL). This inclusion is\nexpected to bring clinically meaningful benefits to a greater number of\npatients with BC and NSCLC. Additionally, sac-TMT has been granted six\nBreakthrough Therapy Designations by the NMPA.\n\nSac-TMT is the world's first TROP2 ADC drug approved for marketing in lung\ncancer. Two new indication applications have been accepted for review by the\nNMPA: 1) sac-TMT in combination with pembrolizumab as first‑line treatment\nfor locally advanced or metastatic NSCLC who have programmed cell death ligand\n1 (PD-L1) tumor proportion score (TPS) ≥1% and are EGFR-negative and\nALK-negative; 2) sac‑TMT as first‑line treatment for patients with\nrecurrent or metastatic TNBC who have a PD‑L1 combined positive score (CPS)\n<10 or have recurred after prior programmed cell death protein 1\n(PD-1)/PD‑L1 inhibitor therapy in the early stage, both of the above two\napplications have been included in the priority review and approval process.\nAs of today, the Company has initiated 9 registrational clinical studies in\nChina. MSD has initiated 18 ongoing global Phase III clinical studies of\nsac-TMT as a monotherapy or in combination with pembrolizumab or other\nanti-cancer agents for several types of cancer. These studies are sponsored\nand led by MSD.\n\nAbout SKB500\n\nSKB500 is a B7-H3-targeted ADC independently developed by the company using\nits OptiDC(TM) platform technology, featuring a site-specific cleavable linker\nand a potent topoisomerase I inhibitor. In the Phase I clinical study, SKB500\ndemonstrated robust efficacy and manageable safety profiles across multiple\nadvanced solid tumors. Currently, two Phase II studies of SKB500 in\nextensive-stage small cell lung cancer (ES-SCLC) and advanced esophageal\nsquamous cell carcinoma (ESCC),etc. are ongoing in China.\n\nAbout Kelun-Biotech\n\nKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which\nfocuses on the R&D, manufacturing, commercialization and global collaboration\nof innovative biological drugs and small molecule drugs. Kelun-Biotech focuses\non major disease areas such as solid tumors, autoimmune, and metabolic\ndiseases, and in establishing a globalized drug development and\nindustrialization platform to address the unmet medical needs in China and the\nrest of world. Kelun-Biotech is committed to becoming a leading global\nenterprise in the field of innovative drugs. At present, Kelun-Biotech has\nmore than 30 ongoing key innovative drug projects, of which 4 projects with 8\nindications have been approved for marketing, 2 projects with 3 indications\nare in the NDA stage and more than 10 projects are in the clinical stage.\nKelun-Biotech has established one of the world's leading proprietary ADC and\nnovel DC platforms, OptiDC(TM), and has 2 ADC projects with 5 indications\napproved for marketing, and multiple ADC and novel DC assets in clinical or\npreclinical research stage. For more information, please visit:\nhttps://en.kelun-biotech.com/.\n\n ([1])MSD is the tradename of Merck & Co., Inc, Rahway, NJ, USA.    \n\nView original content to download\nmultimedia:https://www.prnewswire.com/apac/news-releases/kelun-biotech-to-present-multiple-study-results-at-esmo-2026-302906988.html\n\nSOURCE Kelun-Biotech\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1883382/20260715041831EDT_image_1.jpg?id=OA3015499\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-13T11:23:44.788892306Z","server_sent_at_ms":1791890624788},"received_at":"2026-10-13T11:23:44.840Z","source_url":null},"analysis":{"id":"155627","press_release_id":"167322","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Kelun-Biotech will present multiple clinical study results at the ESMO 2026 Congress in Madrid (October 23-27), centered on its TROP2 ADC sac-TMT and the B7-H3 ADC SKB500.\n\nMultiple sac-TMT datasets were selected for oral presentations, including Phase III OptiTROP-Lung04 and OptiTROP-Lung06 in metastatic NSCLC, and the MSD-led global pivotal Phase III TroFuse-005 endometrial cancer trial will debut in the ESMO Presidential Symposium.\n\nSac-TMT already has four approved indications in China (two on the NRDL) and is the world's first TROP2 ADC approved in lung cancer; selection for high-profile sessions is a positive pipeline signal, but no efficacy data is disclosed until the congress.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Watch the October 25 NSCLC proffered-paper session and TroFuse-005 Presidential Symposium readouts as near-term catalysts for sac-TMT and the MSD partnership."},"keyFigures":{"drugName":"sacituzumab tirumotecan (sac-TMT / SKB264 / MK-2870)","phaseOfTrial":"Phase 3","customDimensions":{"dar":7.4,"congress":"ESMO 2026, Madrid, October 23-27","msd_global_phase3_studies":18,"approved_china_indications":4,"registrational_studies_china":9,"breakthrough_designations_nmpa":6}},"namedEntities":{"people":[],"products":["sacituzumab tirumotecan (sac-TMT, SKB264/MK-2870, 佳泰莱)","SKB500","pembrolizumab","OptiDC platform"],"companies":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"6990","relationship":"filer"},{"name":"MSD (Merck & Co., Inc.)","relationship":"partner; holds ex-Greater China rights to sac-TMT and leads global Phase III TroFuse-005"},{"name":"Kelun Pharmaceutical","relationship":"parent"},{"name":"European Society for Medical Oncology (ESMO)","relationship":"congress organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"This is a conference-presentation announcement, not new data: multiple sac-TMT Phase III studies (OptiTROP-Lung04/06, TroFuse-005) were selected for oral and Presidential Symposium sessions at ESMO 2026, a positive signal for the pipeline but no results are disclosed yet."},"tickerRelevance":{"others":[],"primary":"6990"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"conference-announcement (no data yet)","sectorWeight":"oncology/ADC high-interest","partnershipWeight":"MSD-led global Phase III program"}},"event_type":"clinical_trial","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Kelun-Biotech will present multiple clinical study results at the ESMO 2026 Congress in Madrid (October 23-27), centered on its TROP2 ADC sac-TMT and the B7-H3 ADC SKB500.\n\nMultiple sac-TMT datasets were selected for oral presentations, including Phase III OptiTROP-Lung04 and OptiTROP-Lung06 in metastatic NSCLC, and the MSD-led global pivotal Phase III TroFuse-005 endometrial cancer trial will debut in the ESMO Presidential Symposium.\n\nSac-TMT already has four approved indications in China (two on the NRDL) and is the world's first TROP2 ADC approved in lung cancer; selection for high-profile sessions is a positive pipeline signal, but no efficacy data is disclosed until the congress.","key_figures":{"drugName":"sacituzumab tirumotecan (sac-TMT / SKB264 / MK-2870)","phaseOfTrial":"Phase 3","customDimensions":{"dar":7.4,"congress":"ESMO 2026, Madrid, October 23-27","msd_global_phase3_studies":18,"approved_china_indications":4,"registrational_studies_china":9,"breakthrough_designations_nmpa":6}},"named_entities":{"people":[],"products":["sacituzumab tirumotecan (sac-TMT, SKB264/MK-2870, 佳泰莱)","SKB500","pembrolizumab","OptiDC platform"],"companies":[{"name":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","ticker":"6990","relationship":"filer"},{"name":"MSD (Merck & Co., Inc.)","relationship":"partner; holds ex-Greater China rights to sac-TMT and leads global Phase III TroFuse-005"},{"name":"Kelun Pharmaceutical","relationship":"parent"},{"name":"European Society for Medical Oncology (ESMO)","relationship":"congress organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:23:51.645Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"conference-announcement (no data yet)","sectorWeight":"oncology/ADC high-interest","partnershipWeight":"MSD-led global Phase III program"}},"durationMs":6786,"modelName":"glm-5.3-flashx"}}